The Brugada syndrome (BrS) and long-QT syndrome (LQTS) present as congenital or acquired disorders with diagnostic electrocardiograms (ST-segment elevation and prolonged QT interval, respectively) and increased risk for malignant arrhythmias. Our understanding of the 2 disease forms (congenital vs. acquired) differs. A female patient on quinidine for atrial fibrillation who develops ventricular fibrillation is diagnosed with "acquired LQTS" and is discharged with no therapy other than instructions to avoid QT-prolonging medications. In contrast, an asymptomatic male patient who develops a Brugada electrocardiogram on flecainide is diagnosed with "asymptomatic BrS" and could be referred for an electrophysiological evaluation that could result in defibrillator implantation. The typical patient undergoing defibrillator implantation for BrS is asymptomatic but has a Brugada electrocardiogram provoked by a drug. The authors describe how the histories of LQTS and BrS went through the same stages, but in different sequences, leading to different conclusions. (J Am Coll Cardiol 2016;67:100-8)
Other drugs were soon found to display comparable effects on the QT segment, with similar consequences, making diLQTS a recognized entity. This phenomenon became even more intriguing as medications with noncardiac indications (naturally assumed to have no cardiac effects) were recognized to display proarrhythmic effects. The first was the antipsychotic drug thioridazine (17) . Ironically, as described earlier, quinidine was used at some point to treat this new form of diLQTS (17) . The medical community would have to wait until the 1990s before the mechanism of QT prolongation by noncardiac drugs would finally be understood. Havakuk and Viskin
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UNDERSTANDING diLQTS. During the first decades after its recognition, diLQTS was considered "idiosyncratic," simply unpredictable, although high-risk characteristics (older women, patients with heart failure) had been recognized (28) . In 1981 (11 years before the discovery of the genes responsible for The same year, Jackman et al. (31) demonstrated that patients with drug-induced TdP were at higher risk for recurrence when exposed to a second offending drug and that their QT intervals tended to be at the upper end of the normal range, even before drug exposure. This led them to propose an "inborn predisposition" as the etiology for diLQTS (31) . The unraveled mechanism of cLQTS (as described earlier) now served to establish I Kr blockade as the cause of diLQTS (32) . Yet the question of who is prone to diLQTS remained unanswered.
In 1998, Roden (33) wrote a brief editorial, "Taking the 'Idio' out of 'Idiosyncratic': Predicting Torsades carrying the mutant gene, resulting in seemingly normal QT intervals that were unmasked only after exposure to a repolarization challenge (35, 36) . The overlap between congenital and acquired LQTS was finally understood to some extent. Young, ostensibly healthy men with this peculiar electrocardiographic pattern were considered at risk for impending doom, as cardiac arrest rates for initially asymptomatic patients appeared to be as high as 10% per year (63) . Given the contemporary availability of ICDs, it seemed logical to advise such asymptomatic patients (if they had inducible VF during EPS) to undergo ICD implantation (64,65). As discussed in detail (66), these recommendations were also applied to asymptomatic patients who had their BrS "unraveled" by sodium-channel-blocker tests.
EVOLUTION OF DIAGNOSTIC PRINCIPLES
The DEBUT (Defibrillator Versus b-Blockers for Unexplained Death in Thailand) randomized study, conducted in the 1990s, comparing drug therapy with ICD therapy for BrS with cardiac arrest or malignant syncope (65) , was prematurely stopped because of the unacceptably high mortality rate in the medication arm. Regrettably, the medication used in the "drug arm" of this trial (propranolol) was the wrong drug to test. In fact, this beta-blocker with sodium-channel-blocker properties is now listed among the "drugs to preferably avoid" in BrS (62) . By the time the DEBUT trial was designed, quinidine had already been successfully used to prevent recurrent arrhythmias in idiopathic VF (67, 68) , and shortly after publication of the DEBUT trial, quinidine was also found to be effective in BrS (69, 70) . By now, however, the ICD was already "the only acceptable therapy" for BrS (58) . As the years passed, accumulating data showed that the rates of sudden deaths in patients with BrS were much lower for the subgroup that was asymptomatic at the time of diagnosis (71) , and the therapeutic approach was challenged. Nevertheless, these patients were (and still are) referred for EPS and may undergo ICD implantation (72) .
ACT III: LOOKING BACK TO UNDERSTAND HOW WE GOT HERE "History never looks like history when you are living through it." -John W. Gardner (73) The therapeutic approach to asymptomatic patients radically differs between BrS and LQTS. This is due in part to the less forgiving course of BrS; only a minority of patients with BrS will develop arrhythmias, but for those who do, cardiac arrest is often the presenting symptom (74) . In contrast, in LQTS, patients with cardiac arrest often have warning symptoms in the form of syncope, or identifiable high-risk characteristics, such as a very long QT interval (75) . Also, the safety profile in terms of adverse events is better for beta-blockers than for quinidine.
However, history also appears to have influenced the way these patients are treated. By 2006, one-half of the ICD implantations performed in Europe for BrS were in completely asymptomatic patients. Moreover, the most common indication for ICD implantation in the asymptomatic group was a "positive ajmaline test with positive EPS" (76) . Sure enough, at revealed by the ajmaline test had experienced spontaneous VF, whereas 31% had serious ICD-related complications (76) . Publication of these numbers eventually led to a more conservative approach, and nowadays, the proportion of ICD implantations for asymptomatic BrS, particularly that "revealed by drugs," is decreasing, at least in academic institutions (72) . Prophylactic defibrillator implantation for asymptomatic patients who develop long QT intervals when challenged by medications would be unthinkable to most of us. To understand how we ended up with so many ICDs in asymptomatic patients with drug-exposed Brugada ECGs, we ought to look back at how the understanding of LQTS and BrS evolved over the years. 
